A review of melatonin in hepatic ischemia/reperfusion injury and clinical liver disease

References

• Yang Y, Duan W, Jin Z, Yi W, Yan J, Zhang S, et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res. 2013;55:275–86.
   PubMed Web of Science ®Google Scholar
• Koh PO. Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J Pineal Res. 2012;53: 358–65.
   PubMed Web of Science ®Google Scholar
• Sezgin G, Oztürk G, Güney S, Sinanoğlu O, Tunçdemir M. Protective effect of melatonin and 1,25-dihydroxyvitamin D3 on renal ischemia-reperfusion injury in rats. Ren Fail. 2013;35:374–9.
   PubMed Web of Science ®Google Scholar
• Sewerynek E, Reiter RJ, Melchiorri D, Ortiz GG, Lewinski A. Oxidative damage in the liver induced by ischemia/reperfusion: protection by melatonin. Hepatogastroenterology. 1996;43:898–905.
   PubMedGoogle Scholar
• Hernández JA. [Effect of pretreatment with melatonin on the oxidative and inflammatory damage induced by hepatic ischemia/reperfusion in Zucker rats]. An R Acad Nac Med (Madr). 2011;128:391–415. [In Spanish]
   Google Scholar
• Sener G, Tosun O, Sehirli AO, Kacmaz A, Arbak S, Ersoy Y, et al. Melatonin and N-acetylcysteine have beneficial effects during hepatic ischemia and reperfusion. Life Sci. 2003;72:2707–18.
   PubMed Web of Science ®Google Scholar
• Kang JW, Koh EJ, Lee SM. Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J Pineal Res. 2011;50:403–11.
   PubMed Web of Science ®Google Scholar
• Liang R, Nickkholgh A, Hoffmann K, Kern M, Schneider H, Sobirey M, et al. Melatonin protects from hepatic reperfusion injury through inhibition of IKK and JNK pathways and modification of cell proliferation. J Pineal Res. 2009;46:8–14.
   PubMed Web of Science ®Google Scholar
• Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol. 2005;165:139–49.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci. 2000;7:444–58.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res. 2004;36:1–9.
   PubMed Web of Science ®Google Scholar
• Ahmadiasl N, Banaei S, Alihemmati A, Baradaran B, Azimian E. The anti-inflammatory effect of erythropoietin and melatonin on renal ischemia reperfusion injury in male rats. Adv Pharm Bull. 2014; 4:49–54.
   PubMedGoogle Scholar
• Reiter RJ, Oh CS, Fujimori O. Melatonin its intracellular and genomic actions. Trends Endocrinol Metab. 1996;7:22–7.
   PubMed Web of Science ®Google Scholar
• Bharti VK, Srivastava RS, Kumar H, Bag S, Majumdar AC, Singh G, et al. Effects of melatonin and epiphyseal proteins on fluoride-induced adverse changes in antioxidant status of heart, liver, and kidney of rats. Adv Pharmacol Sci. 2014;2014:532969.
   Google Scholar
• Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous hydroxyl radical scavenger. J Endocrinol. 1993; 1:57–60.
   Google Scholar
• Rodriguez AB, Nogales G, Marchena JM, Ortega E, Barriga C. Suppression of both basal and antigen-induced lipid peroxidation in ring dove heterophils by melatonin. Biochem Pharmacol. 1999;58:1301–6.
   Google Scholar
• Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res. 2006;40:168–76.
   PubMed Web of Science ®Google Scholar
• Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Physiological concentrations of melatonin inhibit nitric oxide synthase in rat cerebellum. Life Sci. 1994;55:PL455–60.
   PubMed Web of Science ®Google Scholar
• León J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res. 2005;38:1–9.
   PubMed Web of Science ®Google Scholar
• Espino J, Bejarano I, Paredes SD, González D, Barriga C, Reiter RJ, et al. Melatonin counteracts alterations in oxidative metabolism and cell viability induced by intracellular calcium overload in human leucocytes: changes with age. Basic Clin Pharmacol Toxicol. 2010; 107:590–7.
   Google Scholar
• Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci. 2004;75:765–90.
   PubMed Web of Science ®Google Scholar
• Espino J, Bejarano I, Redondo PC, Rosado JA, Barriga C, Reiter RJ, et al. Melatonin reduces apoptosis induced by calcium signaling in human leukocytes: evidence for the involvement of mitochondria and bax activation. J Membr Biol. 2010;233:105–18.
   PubMed Web of Science ®Google Scholar
• Espino J, Bejarano I, Paredes SD, Barriga C, Rodríguez AB, Pariente JA. Protective effect of melatonin against human leukocyte apoptosis induced by intracellular calcium overload: relation with its antioxidant actions. J Pineal Res. 2011;51:195–206.
   PubMed Web of Science ®Google Scholar
• Javeshghani D, Barhoumi T, Idris-Khodja N, Paradis P, Schiffrin EL. Reduced macrophage-dependent inflammation improves endothelin-1-induced vascular injury. Hypertension. 2013;62:112–17.
   PubMed Web of Science ®Google Scholar
• Risbano MG, Gladwin MT. Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. Handb Exp Pharmacol. 2013;218:315–49.
   Google Scholar
• Shah V, Kamath PS. Nitric oxide in liver transplantation: pathobiology and clinical implications. Liver Transpl. 2003;9:1–11.
   Google Scholar
• Albrecht EW, Stegeman CA, Heeringa P, Henning RH, van Goor H. Protective role of endothelial nitric oxide synthase. J Pathol. 2003;199: 8–17.
   PubMed Web of Science ®Google Scholar
• Marletta MA. Nitric oxide synthase: aspects concerning structure and catalysis. Cell. 1994;78:927–30.
   PubMed Web of Science ®Google Scholar
• Dalkara T, Endres M, Moskowitz MA. Mechanisms of NO neurotoxicity. Prog Brain Res. 1998;118:231–9.
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Dostert P, Marrari P, Cini M. Effect of ageing on tissue levels of amino acids involved in the nitric oxide pathway in rat brain. J Neural Transm Gen Sect. 1993;94:21–30.
   Google Scholar
• Soltis EE. Effect of age on blood pressure and membrane dependent vascular responses in the rat. Circ Res. 1987;61:889–97.
   Google Scholar
• Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol. 1995;269:H550–5.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Reynoso S, Leal C, Portilla E, Olivares N, Muniz J. Effect of exogenous melatonin on hepatic energetic status during ischemia/reperfusion: possible role of tumor necrosis factor-α and nitric oxide. J Surg Res. 2001;100:141–9.
   PubMed Web of Science ®Google Scholar
• Kilic U, Kilic E, Reiter RJ, Bassetti CL, Hermann DM. Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice. J Pineal Res. 2005;38:67–71.
   PubMed Web of Science ®Google Scholar
• Wang WZ, Fang XH, Stephenson LL, Baynosa RC, Khiabani KT, Zamboni WA. Microcirculatory effects of melatonin in rat skeletal muscle after prolonged ischemia. J Pineal Res. 2005;39:57–65.
   Google Scholar
• Zhang WH, Li JY, Zhou Y. Melatonin abates liver ischemia/reperfusion injury by improving the balance between nitric oxide and endothelin. Hepatobiliary Pancreat Dis Int. 2006;5:574–9.
   Google Scholar
• Zamzami N, Hirsch T, Dallaporta B, Petit PX, Kroemer G. Mitochondrial implication in accidental and programmed cell death: apoptosis and necrosis. J Bioenerg Biomembr. 1997;29:185–93.
   PubMed Web of Science ®Google Scholar
• Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J. 1999;341:233–49.
   PubMed Web of Science ®Google Scholar
• Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.
   PubMed Web of Science ®Google Scholar
• Frederiks WM, Vogels IM, Fronik GM. Plasma ornithine carbamyl transferase level as an indicator of ischaemic injury of rat liver. Cell Biochem Funct. 1984;2:217–20.
   Google Scholar
• Okatani Y, Wakatsuki A, Reiter RJ, Enzan H, Miyahara Y. Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol. 2003;469:145–52.
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee SM. Cytoprotective effects of melatonin against necrosis and apoptosis induced by ischemia/reperfusion injury in rat liver. J Pineal Res. 2008;44:165–71.
   PubMed Web of Science ®Google Scholar
• Venegas C, García JA, Escames G, Ortiz F, López A, Doerrier C, et al. Extrapineal melatonin: analysis of its subcellular distribution and daily fluctuations. J Pineal Res. 2012;52:217–27.
   PubMed Web of Science ®Google Scholar
• Kireev R, Bitoun S, Cuesta S, Tejerina A, Ibarrola C, Moreno E, et al. Melatonin treatment protects liver of Zucker rats after ischemia/ reperfusion by diminishing oxidative stress and apoptosis. Eur J Pharmacol. 2013;701:185–93.
   PubMed Web of Science ®Google Scholar
• Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, et al. Mitochondrial adaptations to obesity related oxidant stress. Arch Biochem Biophys. 2000;378:259–68.
   PubMed Web of Science ®Google Scholar
• Jou MJ, Peng TI, Yu PZ, Jou SB, Reiter RJ, Chen JY, et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res. 2007;43: 389–403.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Chyan YJ, Poeggeler B, Bozner P, Ghiso J, Le Daux SP, et al. Alzheimer h protein mediated oxidative damage to mitochondrial DNA: prevention by melatonin. J Pineal Res. 1999;27:226–9.
   PubMed Web of Science ®Google Scholar
• Jiménez-Aranda A, Fernández-Vázquez G, Campos D, Tassi M, Velasco-Perez L, Tan DX, et al. Melatonin induces browning of inguinal white adipose tissue in Zucker diabetic fatty rats. J Pineal Res. 2013;55:416–23.
   PubMed Web of Science ®Google Scholar
• Mattiasson G, Sullivan PG. The emerging functions of UCP2 in health, disease, and therapeutics. Antioxid Redox Signal. 2006;8:1–38.
   PubMed Web of Science ®Google Scholar
• Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans. 2006;34:232–7.
   PubMed Web of Science ®Google Scholar
• Garcia JJ, Reiter RJ, Guerrero JM, Escames G, Yu BP, Oh CS, et al. Melatonin prevents changes in microsomal membrane fluidity during induced lipid peroxidation. FEBS Lett. 1997;408:297–300.
   PubMed Web of Science ®Google Scholar
• Maines MD. The heme oxygenase system: a regulator of second messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517–54.
   PubMed Web of Science ®Google Scholar
• Zhu X, Fan WG, Li DP, Kung H, Lin MC. Heme oxygenase-1 system and gastrointestinal inflammation: a short review. World J Gastroenterol. 2011;17:4283–8.
   PubMed Web of Science ®Google Scholar
• Shen XD, Ke B, Zhai Y, Gao F, Anselmo D, Lassman CR, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology. 2003;37:296–303.
   PubMed Web of Science ®Google Scholar
• Shen XD, Ke B, Zhai Y, Gao F, Busuttil RW, Cheng G, et al. Toll- like receptor and heme oxygenase-1 signaling in hepatic ischemia/reperfusion injury. Am J Transplant. 2005;5:1793–800.
   PubMedGoogle Scholar
• Kang JW, Lee SM. Melatonin inhibits type 1 interferon signaling of toll-like receptor 4 via heme oxygenase-1 induction in hepatic ischemia/reperfusion. J Pineal Res. 2012;53:67–76.
   PubMed Web of Science ®Google Scholar
• Tsuchihashi S, Zhai Y, Bo Q, Busuttil RW, Kupiec-Weglinski JW. Heme oxygenase-1 mediated cytoprotection against liver ischemia and reperfusion injury: inhibition of type-1 interferon signaling. Transplantation. 2007;83:1628–34.
   PubMedGoogle Scholar
• O'neill LA. Therapeutic targeting of Toll-like receptors for inflammatory and infectious diseases. Curr Opin Pharmacol. 2003;3:396–403.
   PubMed Web of Science ®Google Scholar
• Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med. 2005;201:1135–43.
   PubMed Web of Science ®Google Scholar
• Hertzog PJ, O'neill LA, Hamilton JA. The interferon in TLR signaling: more than just antiviral. Trends Immunol. 2003;24:534–9.
   PubMed Web of Science ®Google Scholar
• Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, et al. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med. 2008;205:2609–21.
   PubMed Web of Science ®Google Scholar
• Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, et al. Inflammatory regulation by TLR3 in acute hepatitis. J Immunol. 2009;183:3712–19.
   Google Scholar
• Tsung A, Hoffman RA, Izuishi K, Critchlow ND, Nakao A, Chan MH, et al. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J Immunol. 2005;175:7661–8.
   PubMed Web of Science ®Google Scholar
• Huang SH, Cao XJ, Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophages. J Pineal Res. 2008;45:93–100.
   PubMed Web of Science ®Google Scholar
• Huang G, Shi LZ, Chi H. Regulation of JNK and p38 MAPK in the immune system: signal integration, propagation and termination. Cytokine. 2009;48:161–9.
   PubMed Web of Science ®Google Scholar
• Johnson GL, Nakamura K. The c-Jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta. 2007;1773:1341–8.
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290:583–9.
   PubMed Web of Science ®Google Scholar
• Schemmer P, Schoonhoven R, Swenberg JA, Bunzendahl H, Thurman RG. Gentle in situ liver manipulation during organ harvest decreases survival after rat liver transplantation: role of Kupffer cells. Transplantation. 1998;65:1015–20.
   PubMed Web of Science ®Google Scholar
• Fan C, Li Q, Zhang Y, Liu X, Luo M, Abbott D, et al. IkappaBalpha and IkappaBbeta possess injury context-specific functions that uniquely influence hepatic NF-kappaB induction and inflammation. J Clin Invest. 2004;113:746–55.
   PubMed Web of Science ®Google Scholar
• Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, et al. NK mediates hepatic ischemia reperfusion injury. J Hepatol. 2005;42: 850–9.
   PubMed Web of Science ®Google Scholar
• Schemmer P, Nickkholgh A, Schneider H, Sobirey M, Weigand M, Koch M, et al. PORTAL: pilot study on the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection: a double-blind randomized placebo-controlled trial. BMC Surg. 2008;8:2.
   Google Scholar
• Freitas I, Bertone V, Guarnaschelli C, Ferrigno A, Boncompagni E, Rizzo V, et al. In situ demonstration of improvement of liver mitochondria function by melatonin after cold ischemia. In Vivo. 2006;20: 229–37.
   PubMedGoogle Scholar
• Casillas-Ramírez A, Mosbah IB, Ramalho F, Roselló-Catafau J, Peralta C. Past and future approaches to ischemia-reperfusion lesion associated with liver transplantation. Life Sci. 2006;79:1881–94.
   PubMed Web of Science ®Google Scholar
• Pashkov AN, Popov SS, Semenikhina AV, Rakhmanova TI. Glutathione system and activity of NADPH-generating enzymes in the liver of intact rats and animals with toxic hepatitis receiving melatonin. Bull Exp Biol Med. 2005;139:565–8.
   Google Scholar
• Popov SS, Shul’gin KK, Pashkov AN, Zoloedov VI, Shvedov GI. [Intensity of free radical oxidation and superoxide dismutase activity in patients with drug hepatitis in combination therapy with melaxen or epifamin]. Eksp Klin Gastroenterol. 2011;9:36–40. [In Russian]
   Google Scholar
• Popov SS, Pashkov AN, Zoloedov VI, Shvedov GI. The use of melatonin in combined therapy of drug-induced hepatitis. Klin Med (Mosk). 2013;91:50–3.
   Google Scholar
• Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol. 2002;54:1299–321.
   PubMed Web of Science ®Google Scholar
• Fourman LT, Robert Meyer B. Autoimmune hepatitis in association with ramelteon. J Clin Gastroenterol. 2013;47:651–4.
   PubMed Web of Science ®Google Scholar
• Cuesta S, Kireev R, Forman K, García C, Escames G, Ariznavarreta C, et al. Melatonin improves inflammation processes in liver of senescence-accelerated prone male mice (SAMP8). Exp Gerontol. 2010; 45:950–6.
   Google Scholar
• Zaouali MA, Boncompagni E, Reiter RJ, Bejaoui M, Freitas I, Pantazi E, et al. AMPK involvement in endoplasmic reticulum stress and autophagy modulation after fatty liver graft preservation: a role for melatonin and trimetazidine cocktail. J Pineal Res. 2013;55:65–78.
   PubMed Web of Science ®Google Scholar
• Cichoz-Lach H, Celinski K, Konturek PC, Konturek SJ, Slomka M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol. 2010; 61:577–80.
   PubMed Web of Science ®Google Scholar
• Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, et al. The pilot study of 3-month course of melatonin treatment of patients with nonalcoholic steatohepatitis: effect on plasma levels of liver enzymes, lipids and melatonin. J Physiol Pharmacol. 2010;61:705–10.
   PubMed Web of Science ®Google Scholar
• Gonciarz M, Gonciarz Z, Bielanski W, Mularczyk A, Konturek PC, Brzozowski T, et al. The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J Physiol Pharmacol. 2012;63:35–40.
   PubMed Web of Science ®Google Scholar
• Celinski K, Konturek PC, Slomka M, Cichoz-Lach H, Gonciarz M, Bielanski W, et al. Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. J Pineal Res. 2009;46:408–14.
   PubMedGoogle Scholar
• Montagnese S, Middleton B, Mani AR, Skene DJ, Morgan MY. On the origin and the consequences of circadian abnormalities in patients with cirrhosis. Am J Gastroenterol. 2010;105:1773–81.
   PubMed Web of Science ®Google Scholar
• Chojnacki C, Walecka-Kapica E, Klupińska G, Wachowska-Kelly P, Żylińska K, Winczyk K, et al. Serotonin and melatonin secretion and metabolism in patients with liver cirrhosis. Pol Arch Med Wewn. 2012;122:392–7.
   Google Scholar
• Chojnacki C, Wachowska-Kelly P, Błasiak J, Reiter RJ, Chojnacki J. Melatonin secretion and metabolism in patients with hepatic encephalopathy. J Gastroenterol Hepatol. 2013;28:342–7.
   Google Scholar
• Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 2012;52:282–90.
   Google Scholar
• Subramanian P, Mirunalini S, Dakshayani KB, Pandi-Perumal SR, Trakht I, Cardinali DP. Prevention by melatonin of hepatocarcinogenesis in rats injected with N-nitrosodiethylamine. J Pineal Res. 2007; 43:305–12.
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7:189–203.
   PubMed Web of Science ®Google Scholar
• Yan JJ, Shen F, Wang K, Wu MC. Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: a prospective study. Hepatobiliary Pancreat Dis Int. 2002;1:183–6.
   PubMedGoogle Scholar
• Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuro Endocrinol Lett. 2001;2245–7.
   Google Scholar
• Kim KJ, Choi JS, Kang I, Kim KW, Jeong CH, Jeong JW. Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. J Pineal Res. 2013;54:264–70.
   Google Scholar
• Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: metaanalysis. BMJ. 2006;332:385–93.
   PubMed Web of Science ®Google Scholar
• Manda K, Ueno M, Anzai K. AFMK, a melatonin metabolite, attenuates X-ray-induced oxidative damage to DNA, proteins and lipids in mice. J Pineal Res. 2007;42:386–93.
   PubMed Web of Science ®Google Scholar
• Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28–42.
   PubMed Web of Science ®Google Scholar
• Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res. 2006;41:337–43.
   PubMed Web of Science ®Google Scholar
• Morera AL, Henry M, de La Varga M. Safety in melatonin use. Actas Esp Psiquiatr. 2001;29:334–37.
   Google Scholar